Skip to content

Ascendis Pharma A/S

US · ASND #1127 by market cap Listed 2015
252.73 -3.23 -1.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Mixed / stable
  • The number of reporting institutions decreased by 2 in the most recent period (2026/Q4).
  • Total institutional ownership (as a % of shares) was little changed.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
106.01% -0.04pp
Institutions
421 -2
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund71.27%
VC/PE Fund18.45%
Hedge Fund11.78%
Public Company2.29%
Private Company0.90%
Government Pension Fund0.51%
Sovereign Wealth Fund0.33%
Family Office/Trust0.17%
Insurance Company0.16%

Top holders as of 2026-09-30

RA Capital Management, L.P. 15.67% · 10.28M sh
T. Rowe Price Group, Inc. 13.89% · 9.11M sh
Westfield Capital Management Company, L.P. 7.81% · 5.13M sh
Avoro Capital Advisors LLC 7.70% · 5.05M sh
Janus Henderson Group plc 5.57% · 3.65M sh
FMR 5.25% · 3.45M sh
Wellington Management Group 4.68% · 3.07M sh
Capital Research 3.61% · 2.37M sh
BlackRock 3.48% · 2.28M sh
MFS Investment Management 2.86% · 1.88M sh
Artisan Partners Limited Partnership 3.18% · 2.08M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 6 buys · 4 sells

NameRoleStake
Pedersen Anni Lotte Sonderbjerg Executive VP, Chief Administrative Officer & Member of the Executive Board 0.03%
Scott Smith CFO, Executive VP & Member of Executive Board 0.01%
Lars Holtug Independent Director 0.01%
Jean-Jacques Bienaime Non-Executive Director 0.00%
Albert Cha Independent Chairperson --
Jan Mikkelsen President, CEO, Member of Executive Board & Executive Director --
Michael Jensen Executive VP, Chief Legal Officer & Member of the Executive Board --
Flemming Jensen Executive Vice President of Product Supply & Quality --
Mads Bodenhoff Senior VP, Head of Finance & Principal Accounting Officer --
William Fairey Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-07 Mads Bodenhoff Senior VP, Head of Finance & Principal Accounting Officer Derivative Exercise and Sale -3,000 $110.00–270.19
2026-09-01 Lars Holtug Independent Director Open Market Disposition -236 $264.13
2026-08-13 Jean-Jacques Bienaime Non-Executive Director Open Market Acquisition +2,000 $245.85–246.91
2026-06-01 Scott Smith CFO, Executive VP & Member of Executive Board Open Market Acquisition +100 $219.00
2026-05-28 Jean-Jacques Bienaime Non-Executive Director Open Market Acquisition +500 $222.30–223.76
2026-05-28 Scott Smith CFO, Executive VP & Member of Executive Board Open Market Acquisition +250 $223.32
2026-05-25 Jean-Jacques Bienaime Non-Executive Director Open Market Acquisition +400 $236.24–239.37
2026-05-10 Flemming Jensen Executive Vice President of Product Supply & Quality Open Market Disposition -19,460 $238.49
2026-04-13 Jean-Jacques Bienaime Non-Executive Director Derivative Sale to Issuer -9,160 --
2026-04-13 Jean-Jacques Bienaime Non-Executive Director Other Derivative Acquisition +9,160 $249.84
2026-03-22 Jean-Jacques Bienaime Non-Executive Director Initial Statement of Beneficial 0 --
2026-03-17 Albert Cha Independent Chairperson Initial Statement of Beneficial 0 --
2026-03-17 Jan Mikkelsen President, CEO, Member of Executive Board & Executive Director Initial Statement of Beneficial 0 --
2026-03-17 Michael Jensen Executive VP, Chief Legal Officer & Member of the Executive Board Initial Statement of Beneficial 0 --
2026-03-17 Flemming Jensen Executive Vice President of Product Supply & Quality Initial Statement of Beneficial 0 --
2026-03-17 Pedersen Anni Lotte Sonderbjerg Executive VP, Chief Administrative Officer & Member of the Executive Board Initial Statement of Beneficial 0 --
2026-03-17 Mads Bodenhoff Senior VP, Head of Finance & Principal Accounting Officer Initial Statement of Beneficial 0 --
2026-03-17 William Fairey Independent Director Initial Statement of Beneficial 0 --
2026-03-17 Lisa Morrison Independent Director Initial Statement of Beneficial 0 --
2026-03-17 Scott Smith CFO, Executive VP & Member of Executive Board Initial Statement of Beneficial 0 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Ascendis Pharma A/S discussion 0 comments

Add a comment